Thelansis

  Multiple myeloma (MM) is a complex hematologic malignancy characterized by the uncontrolled proliferation of clonal plasma cells in the bone marrow. These cells secrete large amounts of immunoglobulins and other non-functional proteins. Being the second most common hematologic malignancy diagnosed, MM presents a considerable challenge in terms of treatment. CAR T-cell therapy is a promising approach for patients whose disease has relapsed or does not respond to prior therapies. CAR T-cell therapy is a specialized treatment with great potential for multiple myeloma patients. It involves genetic modification of a patient's T cells, enabling them to target and attack the multiple myeloma cells using a specific protein called B-cell maturation antigen (BCMA). The Food and Drug Administration (FDA) has approved idecabtagene vicleucel (Abecma) for individuals with multiple myeloma who have not experienced positive responses to at least four previous cancer treatments. Thelansis’s...